Author:
Zungsontiporn Nicha,Ouwongprayoon Pongsakorn,Boonsirikamchai Piyaporn,Leelayuwatanakul Nophol,Vinayanuwattikun Chanida,Moonai Kantika,Khongkhaduead Ekkachai,Thorner Paul Scott,Shuangshoti Shanop,Teerapakpinyo Chinachote
Funder
Chulalongkorn University Faculty of Medicine
Reference37 articles.
1. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations;Mitsudomi;Transl. Lung Cancer Res.,2014
2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
3. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann. Oncol.,2015
4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial;Wu;Lancet Oncol.,2014
5. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J. Clin. Oncol.,2013